Meeting
2014 Genitourinary Cancers Symposium
Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway–targeted therapy and one prior mTOR inhibitor therapy.
Authors
Bernard J. Escudier
Institut Gustave Roussy, Villejuif, France
Bernard J. Escudier , Camillo Porta , Matthew Squires , Cezary Szczylik , Christian K. Kollmannsberger , Bohuslav Melichar , Sun Young Rha , Emilio Esteban , Georg A. Bjarnason , Nicholas J. Vogelzang , Cora N. Sternberg , Michael Shi , Mathab Marker , Robert John Motzer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01223027
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 473)
DOI
10.1200/jco.2014.32.4_suppl.473
Abstract #
473
Poster Bd #
F6
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Microvessel density as a prognostic marker in high-risk renal cell carcinoma.
First Author: Sarah A. Weiss
Poster
2019 Gastrointestinal Cancers Symposium
Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.
First Author: Yingmiao Liu
Poster
2015 Genitourinary Cancers Symposium
Prognostic biomarker exploration for patients with metastatic renal cell carcinoma receiving VEGFR TKI.
First Author: Inkeun Park
Poster
2014 ASCO Annual Meeting
Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial.
First Author: Andrew X. Zhu